|Product Name||Levosalbutamol Tartrate|
|IUPAC Name||4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]- 2-|
(hydroxymethyl) phenol Tartrate
|Appearance||A white to off-white powder.|
|Solubility||Freely solublein water, Insoluble in Acetone, Acetonitrile, Methylene Dichloride. Slightly soluble in Methanol.|
|Patent Status||Product patent – Out of patent|
|Therap.Cat||Levosalbutamol or levalbuterol is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD)|
Levosalbutamol’s bronchodilator properties give it indications in treatment of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma. Like other bronchodilators, it acts by reducing inflammation in the bronchial tubes, and thus shortening or reversing an acute “attack” of shortness of breath or difficulty breathing. Unlike some slower-acting bronchodilators, it is not indicated as a preventative of chronic bronchial inflammation.